VIDEO
What’s Wrong With ICER?
Sometimes economists can have more control than your doctor about whether you get the medicine that treats your condition.
Op-Ed
Should Access to Life-Saving medicines be determined by economic evaluations?
By: Gunnar Esiason
Time is the most precious commodity all of us have. Time is also the first thing we lose when chronic illness comes into our lives. I am living with cystic fibrosis (CF). For me, my life has long revolved around a rigorous daily treatment routine, recurring trips to medical centers and operating rooms, incessant negotiations with insurance providers, days spent too sick to climb the stairs, precious hours tending to my feeding tube and time spent coping with the psychological challenges of living with a terminal illness.
GUIDES
Patients, in consultation with their doctors, should make their own medical decisions. But with increasing frequency, ICER is influencing what treatment options are available for consideration.
What stands between patients and the treatment prescribed by their doctors? This paper explores the drawbacks of ICER’s evidence reports and how those issues affect patients.
InfographicS
SOCIAL IMAGES
General
Numbers that Matter
BLOG
ICER REPORT DAMPENS PROSPECTS FOR CYSTIC FIBROSIS TREATMENT
FINAL ICER REPORT LEAVES CYSTIC FIBROSIS COMMUNITY UNEASY
Economists at the Institute for Clinical and Economic Review advise a whopping 77 percent price discount on new CFTR modulators for cystic fibrosis, according to a final evidence report.
If health plans heed a new report from the Institute for Clinical and Economic Review, patients with few options to treat their cystic fibrosis may soon have fewer still.